c-Met is a marker of pancreatic cancer stem cells and therapeutic target
C Li, JJ Wu, M Hynes, J Dosch, B Sarkar, TH Welling… - Gastroenterology, 2011 - Elsevier
BACKGROUND & AIMS: Growth of many different tumor types requires a population of self-
renewing cancer stem cells (CSCs). c-Met is a marker of normal mouse pancreatic stem and …
renewing cancer stem cells (CSCs). c-Met is a marker of normal mouse pancreatic stem and …
[HTML][HTML] Opportunities and challenges of targeting c-Met in the treatment of digestive tumors
Z Zhang, D Li, H Yun, J Tong, W Liu, K Chai… - Frontiers in …, 2022 - frontiersin.org
At present, a large number of studies have demonstrated that c-Met generally exerts a
crucial function of promoting tumor cells proliferation and differentiation in digestive system …
crucial function of promoting tumor cells proliferation and differentiation in digestive system …
Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting
A Suzuki, H Nakauchi, H Taniguchi - Diabetes, 2004 - Am Diabetes Assoc
During pancreatic development, neogenesis, and regeneration, stem cells might act as a
central player to generate endocrine, acinar, and duct cells. Although these cells are well …
central player to generate endocrine, acinar, and duct cells. Although these cells are well …
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective …
H Jia, G Dai, J Weng, Z Zhang, Q Wang… - Journal of medicinal …, 2014 - ACS Publications
HGF/c-Met signaling has been implicated in human cancers. Herein we describe the
invention of a series of novel triazolopyrazine c-Met inhibitors. The structure–activity …
invention of a series of novel triazolopyrazine c-Met inhibitors. The structure–activity …
Breaking the cycle: targeting of NDRG1 to inhibit bi‐directional oncogenic cross‐talk between pancreatic cancer and stroma
Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy,
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …
with pancreatic stellate cells (PSCs) being a major contributor to this stromal barrier and …
HGF/MET signaling in ovarian cancer
HY Zhou, YL Pon, AST Wong - Current molecular medicine, 2008 - ingentaconnect.com
Ovarian cancer is the leading cause of death from gynecological cancers in North America
and Europe. Despite its clinical significance, the factors that regulate the development and …
and Europe. Despite its clinical significance, the factors that regulate the development and …
[HTML][HTML] Selecting tumor-specific molecular targets in pancreatic adenocarcinoma: paving the way for image-guided pancreatic surgery
SWL de Geus, LSF Boogerd, RJ Swijnenburg… - Molecular imaging and …, 2016 - Springer
Purpose The purpose of this study was to identify suitable molecular targets for tumor-
specific imaging of pancreatic adenocarcinoma. Procedures The expression of eight …
specific imaging of pancreatic adenocarcinoma. Procedures The expression of eight …
A MET Targeting antibody–drug conjugate overcomes gemcitabine resistance in pancreatic cancer
A Cazes, O Betancourt, E Esparza, ES Mose… - Clinical Cancer …, 2021 - AACR
Purpose: Pancreatic cancer is an aggressive disease associated with a poor 5-year overall
survival. Most patients are ineligible for surgery due to late diagnosis and are treated …
survival. Most patients are ineligible for surgery due to late diagnosis and are treated …
Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features
TJ Huang, JY Wang, SR Lin, ST Lian, JS Hsieh - Acta oncologica, 2001 - Taylor & Francis
Overexpression of hepatocyte growth factor receptor (c-met) has been detected in many
human tumors. To investigate the possible involvement of c-met in human gastric …
human tumors. To investigate the possible involvement of c-met in human gastric …
[HTML][HTML] Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
HM Chen, CH Tsai, WC Hung - Oncotarget, 2015 - ncbi.nlm.nih.gov
Foretinib, a multiple kinase inhibitor undergoing clinical trials, could suppress the activity of
hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor …
hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor …